About Adaptive Biotechnologies Corporation
https://www.adaptivebiotech.comAdaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.
CEO
Chad M. Robins
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 147
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
BTIG
Buy
TD Cowen
Buy
Goldman Sachs
Buy
Scotiabank
Sector Outperform
JP Morgan
Overweight
Piper Sandler
Overweight
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
VIKING GLOBAL INVESTORS LP
Shares:29.99M
Value:$541.09M
BLACKROCK, INC.
Shares:13.36M
Value:$240.98M
BLACKROCK INC.
Shares:11.66M
Value:$210.42M
Summary
Showing Top 3 of 312
About Adaptive Biotechnologies Corporation
https://www.adaptivebiotech.comAdaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $93.97M ▲ | $65.53M ▼ | $9.55M ▲ | 10.16% ▲ | $0.06 ▲ | $16.92M ▲ |
| Q2-2025 | $58.88M ▲ | $65.92M ▲ | $-25.61M ▲ | -43.5% ▲ | $-0.17 ▲ | $-18.14M ▲ |
| Q1-2025 | $52.44M ▲ | $65.07M ▲ | $-29.85M ▲ | -56.92% ▲ | $-0.2 ▲ | $-29.6M ▼ |
| Q4-2024 | $47.46M ▲ | $63.25M ▲ | $-33.69M ▼ | -70.99% ▼ | $-0.23 ▼ | $-26.32M ▼ |
| Q3-2024 | $46.44M | $62.4M | $-32.07M | -69.07% | $-0.22 | $-24.57M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $212.77M ▲ | $490.61M ▼ | $286.36M ▼ | $204.44M ▲ |
| Q2-2025 | $197.87M ▲ | $496.64M ▼ | $317.1M ▼ | $179.72M ▼ |
| Q1-2025 | $193.42M ▼ | $510.85M ▼ | $320.63M ▼ | $190.42M ▼ |
| Q4-2024 | $222.29M ▼ | $539.38M ▼ | $336.89M ▲ | $202.71M ▼ |
| Q3-2024 | $243.33M | $558.51M | $334.93M | $223.77M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $9.55M ▲ | $-7.13M ▲ | $17.28M ▲ | $1.68M ▲ | $11.87M ▲ | $-7.54M ▲ |
| Q2-2025 | $-25.59M ▲ | $-12.43M ▲ | $3.35M ▼ | $1.61M ▼ | $-7.47M ▼ | $-13.09M ▲ |
| Q1-2025 | $-29.85M ▲ | $-28.48M ▼ | $25.57M ▲ | $5.45M ▲ | $2.73M ▼ | $-29.74M ▼ |
| Q4-2024 | $-33.72M ▼ | $-12.49M ▲ | $22.12M ▲ | $127K ▲ | $9.76M ▲ | $-12.57M ▲ |
| Q3-2024 | $-32.07M | $-27.07M | $5.29M | $40K | $-21.74M | $-27.41M |
Revenue by Products
| Product | Q2-2021 | Q3-2021 | Q4-2021 | Q1-2021 |
|---|---|---|---|---|
 Development Revenue | $0 ▲ | $0 ▲ | $0 ▲ | $20.00M ▲ |
 Medicare Revenue | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Sequencing Revenue | $0 ▲ | $0 ▲ | $0 ▲ | $20.00M ▲ |
CEO
Chad M. Robins
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 147
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
BTIG
Buy
TD Cowen
Buy
Goldman Sachs
Buy
Scotiabank
Sector Outperform
JP Morgan
Overweight
Piper Sandler
Overweight
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
VIKING GLOBAL INVESTORS LP
Shares:29.99M
Value:$541.09M
BLACKROCK, INC.
Shares:13.36M
Value:$240.98M
BLACKROCK INC.
Shares:11.66M
Value:$210.42M
Summary
Showing Top 3 of 312